Adaptive Biotechnologies Corporation
ADPT
주식 순위
#4135
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
주가
$24.59
마지막 동기화: 2026-10-20
시가총액
$3.92B
변동 (1일)
2.65%
변동 (1년)
41.70%
국가
US
거래 Adaptive Biotechnologies Corporation (ADPT)
카테고리
Healthcare
Adaptive Biotechnologies Corporation (ADPT)의 매출
Jun 2026 기준 매출 TTM: $308.08M
Adaptive Biotechnologies Corporation의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $308.08M입니다. 2024년에 회사는 $178.96M의 수익을 올렸으며 이는 2023년의 $170.28M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Adaptive Biotechnologies Corporation의 수익 기록 (2017 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $308.08M | 11.23% |
| 2025 | $276.98M | 54.77% |
| 2024 | $178.96M | 5.10% |
| 2023 | $170.28M | -8.11% |
| 2022 | $185.31M | 20.06% |
| 2021 | $154.34M | 56.88% |
| 2020 | $98.38M | 15.65% |
| 2019 | $85.07M | 52.83% |
| 2018 | $55.66M | 44.77% |
| 2017 | $38.45M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 3,997.72% |
US
|
|
| $2.23B | 623.19% |
US
|
|
| $15.74B | 5,010.45% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,854.45% |
NL
|
